Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07552558 · ClinicalTrials.gov registry record · Phase 1
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Not yet
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT07552558 is a Phase 1 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 45 participants.
The verdict
NCT07552558, a Phase 1 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive surgical resection for high-risk, locoregionally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). Approximately 6 weeks after end of SBRT, patients will undergo standard of care (SOC) surgical resection followed by SOC adjuvant chemoradiation per National Comprehensive Cancer Network (NCCN) guidelines. Adjuvant therapy is not part of this study and therefore is not dictated by study protocol.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Ficerafusp alfa
- RADIATION Hypofractionated Stereotactic Body Radiotherapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2033-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07552558
The ClinicalTrials.gov registry entry for NCT07552558 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT07552558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07552558 about?
NCT07552558 is a clinical study titled "Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)". The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive surgical resection for high-risk, locoregionally advanced HPV-negative head an...
What is the current status of trial NCT07552558?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2026-06-30. Estimated completion is 2033-08-31.
What interventions are being tested in trial NCT07552558?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Ficerafusp alfa (DRUG), Hypofractionated Stereotactic Body Radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT07552558?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.